| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | 1 | — | 1 | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 118.30 | 93.71 | 44.34 | 31.49 |
| Receivables | 4.25 | 3.25 | 6.59 | 7.14 |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 122.55 | 96.96 | 50.93 | 38.62 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 2.21 | 0.34 | 1.96 | 2.02 |
| ST’ Debt | — | — | — | — |
| Other | 13.32 | 0.16 | 0.17 | — |
| 25.29 | 8.46 | 13.61 | 16.30 |
| 10y | 5y | 3y | |
| Sales | — | — | — |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 0.17 | 2.77 | — | — |
—
|
| ’25 | — | 0.05 | 0.02 | — |
0.06
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (16.00) | (15.92) | — | — |
—
|
| ’25 | (9.96) | (12.59) | (17.41) | (11.25) |
(51.21)
|
| ’24 | (0.59) | (7.38) | (13.32) | (2.32) |
(23.61)
|
| ’23 | — | (29.82) | — | (47.93) |
(47.74)
|
| ’22 | — | (51.03) | — | (97.59) |
(101.52)
|
| ’21 | — | (39.13) | — | (85.47) |
(85.47)
|
| ’20 | — | — | — | (25.62) |
(25.62)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (16.00) | (15.92) | — | — |
—
|
| ’25 | (10.04) | (12.89) | (17.44) | (11.27) |
(51.64)
|
| ’24 | (0.59) | (7.82) | (13.32) | (2.63) |
(24.36)
|
| ’23 | — | (30.09) | — | (48.22) |
(44.88)
|
| ’22 | — | (52.71) | — | (101.80) |
(105.92)
|
| ’21 | — | (42.76) | — | (89.38) |
(89.43)
|
| ’20 | — | — | — | (27.91) |
(27.96)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.34) | (0.27) | — | — |
—
|
| ’25 | (0.19) | (0.23) | (0.31) | (0.27) |
(1.00)
|
| ’24 | — | — | — | — |
(0.28)
|
| ’23 | — | (0.56) | — | — |
(1.08)
|
| ’22 | — | (1.12) | — | (1.03) |
(2.10)
|
| ’21 | — | (3.10) | — | (1.05) |
(3.90)
|
| ’20 | — | — | — | — |
(1.96)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | ‡‡‡‡ | 0.56 | 0.54 | 0.90 | 0.51 | — | — | — |
Low Price
|
| — | — | — | — | — | ‡‡‡‡‡ | 5.99 | 2.84 | 2.66 | 3.28 | — | — | — |
High Price
|
| — | — | — | — | ‡‡‡‡ | ‡‡‡‡‡ | 100 | 81 | 62 | 64 | — | — | — |
Employees
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.42 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | — | — | 26.03 | 0.06 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | — | 100.00% | 100.00% | — | — | — |
Gross Margin
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (117.79) | (61.99) | (15.40) | (55.28) | — | — | — |
EBT
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | (59.17%) | (86,379.69%) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (117.79) | (62.11) | (15.63) | (55.48) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.03 | 0.72 | 0.66 | 0.70 | — | — | — |
Depreciation
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.47 | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| — | — | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | (2.10) | (1.08) | (0.28) | (1.00) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Earnings/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.84) | (0.87) | (0.43) | (0.92) | — | — | — |
Cash Flow/Sh
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.08) | 0.05 | (0.01) | (0.01) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.92) | (0.81) | (0.44) | (0.93) | — | — | — |
Free CF/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.86 | 1.84 | 1.67 | 0.75 | — | — | — |
Book Value/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 55.04 | 55.07 | 55.21 | 55.66 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | — | — | — | 0.00 | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ |
PE Ratio
|
| — | — | — | — | — | — | — | — | 0.00 | 79.23 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | — | — | — | 0.83 | 3.74 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | — | — | — | 0.00 | 57.17 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
EV/Sales
|
| — | — | — | — | — | — | — | — | 0.70 | (2.19) | — | — | — |
EV/FCF
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (101.52) | (47.74) | (23.61) | (51.21) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (4.40) | 2.86 | (0.75) | (0.43) | ‡‡‡‡‡ | — | — |
Capex
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (105.92) | (44.88) | (24.36) | (51.64) | ‡‡‡‡‡ | — | — |
FCF
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 140.16 | 97.26 | 88.50 | 37.32 | — | — | — |
Working Cap'
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.43 | 0.18 | 0.02 | 0.37 | — | — | — |
Total Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (151.99) | (118.12) | (93.68) | (43.97) | — | — | — |
Net Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 157.49 | 101.50 | 92.17 | 41.98 | — | — | — |
Sh' Equity
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (50.78%) | (41.21%) | (13.67%) | (70.51%) | ‡‡‡‡‡ | — | — |
ROA
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | (1,354.36%) | 0.00% | 0.00% | 0.00% | — | — | — |
ROIC
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (54.96%) | (47.96%) | (16.14%) | (82.72%) | ‡‡‡‡‡ | — | — |
ROE
|
Connect Biopharma Holdings Limited (CNTB), a China-based clinical-stage biotech targeting inflammatory diseases, embodies the sector’s classic boom-bust cycle, surging to $29.27 in 2021 before crashing 95% to $0.54 lows amid rate hikes, market corrections, and U.S.-China tensions. Today, shares trade at levels implying profound undervaluation—price-to-book at 0.83 despite a fortress balance sheet boasting $93.7 million in net cash, negligible debt, and funding for 2-3 years of operations—decoupled from improving fundamentals like narrowing losses (EPS to -$0.28 from -$2.10) and nascent 2024 revenue of $26 million from high-margin deals.
Operational efficiency shines through a 40% employee cut, revenue per employee leaping to $420K, and metrics like ROA improving 67% less negative, signaling a pivot from R&D burn to scalability. Analyst forecasts project a rocky 2025 revenue dip followed by explosive growth to $96 million by 2027, driven by Phase 3 catalysts for assets like rademikibart in asthma, though ramped losses and EPS deterioration reflect heavy pipeline investment—yet targets imply 1,500-2,600% upside if trials succeed.
This coiled spring offers multibagger potential for risk-tolerant investors, echoing historical biotech reratings, but hinges on clinical wins amid geopolitical risks and execution pitfalls. Neutral insider activity tempers hype, positioning CNTB for M&A or inflection in a consolidating China biotech landscape.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.